Grant of Interim Extension of the Term of U.S. Patent No. 5,912,231; LOCILEX® (pexiganan), 24307 [2017-10964]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 101 / Friday, May 26, 2017 / Notices
New England Fishery Management
Council; telephone: (978) 465–0492.
SUPPLEMENTARY INFORMATION:
Agenda
The Committee will review Plan
Development Team (PDT) analysis
regarding skate bait possession limits.
They will discuss and select preferred
alternatives for Framework 4 to the
Skate Fishery Management Plan which
modifies skate bait possession limits
and associated measures. The
committee will also review and discuss
PDT analysis, to date, regarding the
upcoming specifications framework
which would set specifications for FYs
2018 and 2019 and would remove the
prohibition on landing barndoor skates.
Other business, as necessary.
Although other non-emergency issues
not on the agenda may come before this
group for discussion, those issues may
not be the subject of formal action
during this meeting. Actions will be
restricted to those issues specifically
listed in this notice and any issues
arising after publication of this notice
that require emergency action under
§ 305(c) of the Magnuson-Stevens
Fishery Conservation and Management
Act, provided the public has been
notified of the Council’s intent to take
final action to address the emergency.
Special Accommodations
This meeting is physically accessible
to people with disabilities. This meeting
will be recorded. Consistent with 16
U.S.C. 1852, a copy of the recording is
available upon request. Requests for
sign language interpretation or other
auxiliary aids should be directed to
Thomas A. Nies, Executive Director, at
(978) 465–0492, at least 5 days prior to
the meeting date.
Authority: 16 U.S.C. 1801 et seq.
Dated: May 22, 2017.
Tracey L. Thompson,
Acting Deputy Director, Office of Sustainable
Fisheries, National Marine Fisheries Service.
[FR Doc. 2017–10778 Filed 5–25–17; 8:45 am]
BILLING CODE 3510–22–P
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No.: PTO–P–2017–0023]
Grant of Interim Extension of the Term
of U.S. Patent No. 5,912,231; LOCILEX®
(pexiganan)
United States Patent and
Trademark Office, Commerce.
ACTION: Notice of Interim patent term
extension.
AGENCY:
VerDate Sep<11>2014
19:14 May 25, 2017
Jkt 241001
The United States Patent and
Trademark Office has issued an order
granting interim extension for a oneyear interim extension of the term of
U.S. Patent No. 5,912,231.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Mary C. Till by telephone at (571) 272–
7755; by mail marked to her attention
and addressed to the Commissioner for
Patents, Mail Stop Hatch-Waxman PTE,
P.O. Box 1450, Alexandria, VA 22313–
1450; by fax marked to her attention at
(571) 273–7755; or by email to
Mary.Till@uspto.gov.
Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to one year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On May 9, 2017, Scripps Research
Institute, the patent owner of record,
timely filed an application under 35
U.S.C. 156(d)(5) for a second interim
extension of the term of U.S. Patent No.
5,912,231. The patent claims a
composition of the active ingredient
pexiganan of the human drug product
LOCILEX®. The application for patent
term extension indicates that New Drug
Application (NDA) 29–930 was
submitted to the Food and Drug
Administration (FDA) on July 24, 1998.
Review of the patent term extension
application indicates that, except for
permission to market or use the product
commercially, the subject patent would
be eligible for an extension of the patent
term under 35 U.S.C. 156, and that the
patent should be extended for one year
as required by 35 U.S.C. 156(d)(5)(B).
Because the regulatory review period
will continue beyond the extended
expiration date of the patent, June 15,
2017, interim extension of the patent
term under 35 U.S.C. 156(d)(5) is
appropriate.
An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
5,912,231 is granted for a period of one
year from the extended expiration date
of the patent.
SUPPLEMENTARY INFORMATION:
Dated: May 22, 2017.
Robert Bahr,
Deputy Commissioner for Patent Examination
Policy, United States Patent and Trademark
Office.
[FR Doc. 2017–10964 Filed 5–25–17; 8:45 am]
BILLING CODE 3510–16–P
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
24307
DEPARTMENT OF COMMERCE
Patent and Trademark Office
Submission for OMB Review;
Comment Request; Trademark Trial
and Appeal Board (TTAB) Actions
The United States Patent and
Trademark Office (USPTO) will submit
to the Office of Management and Budget
(OMB) for clearance the following
proposal for collection of information
under the provisions of the Paperwork
Reduction Act (44 U.S.C. Chapter 35).
Agency: United States Patent and
Trademark Office, Commerce
Title: Trademark Trial and Appeal
Board (TTAB) Actions
OMB Control Number: 0651–0040.
Form Number(s):
• PTO 2120
• PTO 2151
• PTO 2153
• PTO 2188
• PTO 2189
• PTO 2190
Type of Request: Revision of a
currently approved collection.
Number of Respondents: 78,000 per
year.
Average Hours per Response: Between
10 minutes (0.17 hours) and 30 minutes
(0.5 hours) to gather the necessary
information, prepare the materials, and
to submit it to the USPTO, depending
upon the instrument used.
Burden Hours: 15,997.67 hours.
Cost Burden: $5,744,000.00.
Needs and Uses: This information is
required by the Trademark Act of 1946,
Sections 13, 14, and 20, 15 U.S.C. 1063,
1064, and 1070, respectively. The
information in this collection is a matter
of public record and is used by the
public for a variety of private business
purposes related to establishing and
enforcing trademark rights. This
information is important to the public,
as both common law trademark owners
and Federal trademark registrants must
actively protect their own rights. This
collection includes the information
needed by the USPTO to review the
various types of petitions to cancel the
registration of a mark, notices of
opposition to the registration of a mark,
extensions of time to file an opposition,
appeals, and other papers filed in
connection with inter partes and ex
parte proceedings.
Affected Public: Businesses or other
for-profits; not-for-profit institutions.
Frequency: On occasion.
Respondent’s Obligation: Required to
Obtain or Retain Benefits.
OMB Desk Officer: Nicholas A. Fraser,
email: Nicholas_A._Fraser@
omb.eop.gov. Once submitted, the
E:\FR\FM\26MYN1.SGM
26MYN1
]]>Agencies
[Federal Register Volume 82, Number 101 (Friday, May 26, 2017)]
[Notices]
[Page 24307]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-10964]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No.: PTO-P-2017-0023]
Grant of Interim Extension of the Term of U.S. Patent No.
5,912,231; LOCILEX[supreg] (pexiganan)
AGENCY: United States Patent and Trademark Office, Commerce.
ACTION: Notice of Interim patent term extension.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office has issued an
order granting interim extension for a one-year interim extension of
the term of U.S. Patent No. 5,912,231.
FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571)
272-7755; by mail marked to her attention and addressed to the
Commissioner for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450,
Alexandria, VA 22313-1450; by fax marked to her attention at (571) 273-
7755; or by email to Mary.Till@uspto.gov.
SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code,
generally provides that the term of a patent may be extended for a
period of up to five years if the patent claims a product, or a method
of making or using a product, that has been subject to certain defined
regulatory review, and that the patent may be extended for interim
periods of up to one year if the regulatory review is anticipated to
extend beyond the expiration date of the patent.
On May 9, 2017, Scripps Research Institute, the patent owner of
record, timely filed an application under 35 U.S.C. 156(d)(5) for a
second interim extension of the term of U.S. Patent No. 5,912,231. The
patent claims a composition of the active ingredient pexiganan of the
human drug product LOCILEX[supreg]. The application for patent term
extension indicates that New Drug Application (NDA) 29-930 was
submitted to the Food and Drug Administration (FDA) on July 24, 1998.
Review of the patent term extension application indicates that,
except for permission to market or use the product commercially, the
subject patent would be eligible for an extension of the patent term
under 35 U.S.C. 156, and that the patent should be extended for one
year as required by 35 U.S.C. 156(d)(5)(B). Because the regulatory
review period will continue beyond the extended expiration date of the
patent, June 15, 2017, interim extension of the patent term under 35
U.S.C. 156(d)(5) is appropriate.
An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S.
Patent No. 5,912,231 is granted for a period of one year from the
extended expiration date of the patent.
Dated: May 22, 2017.
Robert Bahr,
Deputy Commissioner for Patent Examination Policy, United States Patent
and Trademark Office.
[FR Doc. 2017-10964 Filed 5-25-17; 8:45 am]
BILLING CODE 3510-16-P
